The N-terminal of the estrogen receptor (ERα) mediates transcriptional cross-talk with the retinoic acid receptor in human breast cancer cells

Journal of Steroid Biochemistry and Molecular Biology

Volumn 86, Issue 1, 2003, Pages 1-14

  Rousseau, Caroline ^a   Pettersson, Filippa ^a   Couture, Marie Claude ^a   Paquin, Andre ^a   Galipeau, Jacques ^a   Mader, Sylvie ^b   Miller Jr , Wilson H ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Breast cancer; Estrogen receptor; RARE; Retinoic acid receptor; Transcription

Indexed keywords

4 HYDROXYTAMOXIFEN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR BETA; THYROID HORMONE RECEPTOR; VITAMIN D RECEPTOR;

AMINO TERMINAL SEQUENCE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; DNA BINDING; DNA RESPONSIVE ELEMENT; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; GENE INDUCTION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LIGAND BINDING; PLASMID; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RIBONUCLEASE PROTECTION ASSAY; SIGNAL TRANSDUCTION;

EID: 0042427425     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(03)00255-3     Document Type: Article

References (85)

1. Mangelsdorf D.J., Evans R.M. The RXR heterodimers and orphan receptors. Cell. 83:1995;841-850.
2. Ribeiro R.C., Kushner P.J., Baxter J.D. The nuclear hormone receptor gene superfamily. Annu. Rev. Med. 46:1995;443-453.
3. Mangelsdorf D.J., Thummel C., Beato M.et al. The nuclear receptor superfamily: the second decade. Cell. 83:1995;835-839.
4. Rosenfeld M.G., Glass C.K. Coregulator codes of transcriptional regulation by nuclear receptors. J. Biol. Chem. 276:2001;36865-36868.
5. McKenna N.J., Lanz R.B., O'Malley B.W. Nuclear receptor coregulators: cellular and molecular biology. Endocr. Rev. 20:1999;321-344.
6. Robyr D., Wolffe A.P., Wahli W. Nuclear hormone receptor coregulators in action: diversity for shared tasks. Mol. Endocrinol. 14:2000;329-347.
7. Weigel N.L., Zhang Y. Ligand-independent activation of steroid hormone receptors. J. Mol. Med. 76:1998;469-479.
8. Kato S., Masuhiro Y., Watanabe M., Kobayashi Y., Takeyama K.I., Endoh H., Yanagisawa J. Molecular mechanism of a cross-talk between oestrogen and growth factor signalling pathways. Genes Cells. 5:2000;593-601.
9. Kato S., Endoh H., Masuhiro Y.et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 270:1995;1491-1494.
10. Campbell R.A., Bhat-Nakshatri P., Patel N.M., Constantinidou D., Ali S., Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J. Biol. Chem. 276:2001;9817-9824.
11. Rogatsky I., Trowbridge J.M., Garabedian M.J. Potentiation of human estrogen receptor alpha transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex. J. Biol. Chem. 274:1999;22296-22302.
12. Bunone G., Briand P.A., Miksicek R.J., Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 15:1996;2174-2183.
13. Endoh H., Maruyama K., Masuhiro Y.et al. Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function 1 of human estrogen receptor alpha. Mol. Cell. Biol. 19:1999;5363-5372.
14. Wu X., Li H., Chen J.D. The human homologue of the yeast DNA repair and TFIIH regulator MMS19 is an AF-1-specific coactivator of estrogen receptor. J. Biol. Chem. 276:2001;23962-23968.
15. Kobayashi Y., Kitamoto T., Masuhiro Y., Watanabe M., Kase T., Metzger D., Yanagisawa J., Kato S. p300 mediates functional synergism between AF-1 and AF-2 of estrogen receptor alpha and beta by interacting directly with the N-terminal A/B domains. J. Biol. Chem. 275:2000;15645-15651.
16. Webb P., Nguyen P., Shinsako J.et al. Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Mol. Endocrinol. 12:1998;1605-1618.
17. Jakacka M., Ito M., Weiss J., Chien P.Y., Gehm B.D., Jameson J.L. Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway. J. Biol. Chem. 276:2001;13615-13621.
18. Safe S. Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitam. Horm. 62:2001;231-252.
19. Sanchez R., Nguyen D., Rocha W., White J.H., Mader S. Diversity in the mechanisms of gene regulation by estrogen receptors. Bioessays. 24:2002;244-254.
20. Slack J.L. Biology and treatment of acute progranulocytic leukemia. Curr. Opin. Hematol. 6:1999;236-240.
21. Rubin M., Fenig E., Rosenauer A., Menendez-Botet C., Achkar C., Bentel J.M., Yahalom J., Mendelsohn J., Miller W.H. Jr. 9-cis-Retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein. Cancer Res. 54:1994;6549-6556.
22. Mangiarotti R., Danova M., Alberici R., Pellicciari C. All-trans-retinoic acid (ATRA)-induced apoptosis is preceded by G1 arrest in human MCF-7 breast cancer cells. Br. J. Cancer. 77:1998;186-191.
23. Zhu W.Y., Jones C.S., Kiss A., Matsukuma K., Amin S., De Luca L.M. Retinoic acid inhibition of cell cycle progression in MCF-7 human breast cancer cells. Exp. Cell. Res. 234:1997;293-299.
24. Bischoff E.D., Gottardis M.M., Moon T.E., Heyman R.A., Lamph W.W. Beyond tamoxifen: the retinoid-X-receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma. Cancer Res. 58:1998;479-484.
25. Gottardis M.M., Lamph W.W., Shalinsky D.R., Wellstein A., Heyman R.A. The efficacy of 9-cis-retinoic acid in experimental models of cancer. Breast Cancer Res. Treat. 38:1996;85-96.
26. Thompson H.J., Becci P.J., Moon R.C., Sporn M.B., Newton D.L., Brown C.C., Nurrenbach A., Paust J. Inhibition of 1-methyl-1-nitrosourea-induced mammary carcinogenesis in the rat by the retinoid axerophthene. Arzneimittelforschung. 30:1980;1127-1129.
27. Hunter D.J., Manson J.E., Colditz G.A., Stampfer M.J., Rosner B., Hennekens C.H., Speizer F.E., Willett W.C. A prospective study of the intake of Vitamins C, E, and A and the risk of breast cancer. N. Engl. J. Med. 329:1993;234-240.
28. Veronesi U., De Palo G., Marubini E.et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J. Natl. Cancer Inst. 91:1999;1847-1856.
29. Evans R.M. The steroid and thyroid hormone receptor superfamily. Science. 240:1988;889-895.
30. Lacroix A., Lippman M.E. Binding of retinoids to human breast cancer cell lines and their effects on cell growth. J. Clin. Invest. 65:1980;586-591.
31. Sheikh M.S., Shao Z.M., Chen J.C., Hussain A., Jetten A.M., Fontana J.A. Estrogen receptor-negative breast cancer cells transfected with the estrogen receptor exhibit increased RAR alpha gene expression and sensitivity to growth inhibition by retinoic acid. J. Cell. Biochem. 53:1993;394-404.
32. Rosenauer A., Nervi C., Davison K., Lamph W.W., Mader S., Miller W.H. Jr. Estrogen receptor expression activates the transcriptional and growth-inhibitory response to retinoids without enhanced retinoic acid receptor alpha expression. Cancer Res. 58:1998;5110-5116.
33. Zhu W.Y., Jones C.S., Amin S., Matsukuma K., Haque M., Vuligonda V., Chandraratna R.A., De Luca L.M. Retinoic acid increases tyrosine phosphorylation of focal adhesion kinase and paxillin in MCF-7 human breast cancer cells. Cancer Res. 59:1999;85-90.
34. Niu M.Y., Menard M., Reed J.C., Krajewski S., Pratt M.A. Ectopic expression of cyclin D1 amplifies a retinoic acid-induced mitochondrial death pathway in breast cancer cells. Oncogene. 20:2001;3506-3518.
35. Budd G.T., Adamson P.C., Gupta M.et al. Phase I/II trial of all-trans-retinoic acid and tamoxifen in patients with advanced breast cancer. Clin. Cancer Res. 4:1998;635-642.
36. Jing Y., Zhang J., Waxman S., Mira-y-Lopez R. Upregulation of cytokeratins 8 and 18 in human breast cancer T47D cells is retinoid-specific and retinoic acid receptor-dependent. Differentiation. 60:1996;109-117.
37. Zhou Q., Stetler-Stevenson M., Steeg P.S. Inhibition of cyclin D expression in human breast carcinoma cells by retinoids in vitro. Oncogene. 15:1997;107-115.
38. de The H., del Mar Vivanco-Ruiz M., Tiollais P., Stunnenberg H., Dejean A. Identification of a retinoic acid responsive element in the retinoic acid receptor a gene. Nature. 343:1990;177-180.
39. Lee M.O., Han S.Y., Jiang S., Park J.H., Kim S.J. Differential effects of retinoic acid on growth and apoptosis in human colon cancer cell lines associated with the induction of retinoic acid receptor beta. Biochem. Pharmacol. 59:2000;485-496.
40. Liu Y., Lee M.O., Wang H.G., Li Y., Hashimoto Y., Klaus M., Reed J.C., Zhang X. Retinoic acid receptor beta mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells. Mol. Cell. Biol. 16:1996;1138-1149.
41. Sun S.Y., Wan H., Yue P., Hong W.K., Lotan R. Evidence that retinoic acid receptor beta induction by retinoids is important for tumor cell growth inhibition. J. Biol. Chem. 275:2000;17149-17153.
42. Swisshelm K., Ryan K., Lee X., Tsou H.C., Peacocke M., Sager R. Down-regulation of retinoic acid receptor beta in mammary carcinoma cell lines and its up-regulation in senescing normal mammary epithelial cells. Cell Growth Differ. 5:1994;133-141.
43. Widschwendter M., Berger J., Muller H.M., Zeimet A.G., Marth C. Epigenetic downregulation of the retinoic acid receptor-beta2 gene in breast cancer. J. Mammary Gland Biol. Neoplasia. 6:2001;193-201.
44. Galipeau J., Li H., Paquin A., Sicilia F., Karpati G., Nalbantoglu J. Vesicular stomatitis virus G pseudotyped retrovector mediates effective in vivo suicide gene delivery in experimental brain cancer. Cancer Res. 59:1999;2384-2394.
45. Ory D.S., Neugeboren B.A., Mulligan R.C. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc. Natl. Acad. Sci. U.S.A. 93:1996;11400-11406.
46. Paquin A., Jaalouk D.E., Galipeau J. Retrovector encoding a green fluorescent protein-herpes simplex virus thymidine kinase fusion protein serves as a versatile suicide/reporter for cell and gene therapy applications. Hum. Gene Ther. 12:2001;13-23.
47. Andrews N.C., Faller D.V. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res. 19:1991;2499.
48. Zinn K., DiMaio D., Maniatis T. Identification of two distinct regulatory regions adjacent to the human α-interferon gene. Cell. 34:1984;865-879.
49. Jiang S.Y., Jordan V.C. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J. Natl. Cancer Inst. 84:1992;580-591.
50. Mangelsdorf D.J., Evans R.M. The RXR heterodimers and orphan receptors. Cell. 83:1995;841-850.
51. Berry M., Metzger D., Chambon P. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J. 9:1990;2811-2818.
52. Tzukerman M.T., Esty A., Santiso-Mere D., Danielian P., Parker M.G., Stein R.B., Pike J.W., McDonnell D.P. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol. Endocrinol. 8:1994;21-30.
53. Liu H., Lee E.S., Deb Los Reyes A., Zapf J.W., Jordan V.C. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex. Cancer Res. 61:2001;3632-3639.
54. Dauvois S., Danielian P.S., White R., Parker M.G. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc. Natl. Acad. Sci. U.S.A. 89:1992;4037-4041.
55. Howell A., Osborne C.K., Morris C., Wakeling A.E. ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer. 89:2000;817-825.
56. Hall J.M., Couse J.F., Korach K.S. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J. Biol. Chem. 276:2001;36869-36872.
57. Wijayaratne A.L., McDonnell D.P. The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J. Biol. Chem. 276:2001;35684-35692.
58. Anzick S.L., Kononen J., Walker R.L., Azorsa D.O., Tanner M.M., Guan X.Y., Sauter G., Kallioniemi O.P., Trent J.M., Meltzer P.S. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science. 277:1997;965-968.
59. Webb P., Nguyen P., Shinsako J.et al. Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Mol. Endocrinol. 12:1998;1605-1618.
60. Onate S.A., Boonyaratanakornkit V., Spencer T.E., Tsai S.Y., Tsai M.J., Edwards D.P., O'Malley B.W. The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors. J. Biol. Chem. 273:1998;12101-12108.
61. Gelman L., Zhou G., Fajas L., Raspe E., Fruchart J.C., Auwerx J. p300 interacts with the N- and C-terminal part of PPARgamma2 in a ligand-independent and -dependent manner, respectively. J. Biol. Chem. 274:1999;7681-7688.
62. Lin R.J., Nagy L., Inoue S., Shao W., Miller W.H. Jr., Evans R.M. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature. 391:1998;811-814.
63. Jenster G., Spencer T.E., Burcin M.M., Tsai S.Y., Tsai M.J., O'Malley B.W. Steroid receptor induction of gene transcription: a two-step model. Proc. Natl. Acad. Sci. U.S.A. 94:1997;7879-7884.
64. Sirchia S.M., Ren M., Pili R., Sironi E., Somenzi G., Ghidoni R., Toma S., Nicolo G., Sacchi N. Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res. 62:2002;2455-2461.
65. Kumar V., Green S., Stack G., Berry M., Jin J.R., Chambon P. Functional domains of the human estrogen receptor. Cell. 51:1987;941-951.
66. Kushner P.J., Hort E., Shine J., Baxter J.D., Greene G.L. Construction of cell lines that express high levels of the human estrogen receptor and are killed by estrogens. Mol. Endocrinol. 4:1990;1465-1473.
67. Lundholt B.K., Briand P., Lykkesfeldt A.E. Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways. Breast Cancer Res. Treat. 67:2001;199-214.
68. Liu G., Wu M., Levi G., Ferrari N. Inhibition of cancer cell growth by all-trans-retinoic acid and its analog N-(4-hydroxyphenyl) retinamide: a possible mechanism of action via regulation of retinoid receptors expression. Int. J. Cancer. 78:1998;248-254.
69. Tora L., White J., Brou C., Tasset D., Webster N., Scheer E., Chambon P. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell. 59:1989;477-487.
70. Widschwendter M., Berger J., Daxenbichler G., Muller-Holzner E., Widschwendter A., Mayr A., Marth C., Zeimet A.G. Loss of retinoic acid receptor beta expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer. Cancer Res. 57:1997;4158-4161.
71. Arapshian A., Kuppumbatti Y.S., Mira-y-Lopez R. Methylation of conserved CpG sites neighboring the beta retinoic acid response element may mediate retinoic acid receptor beta gene silencing in MCF-7 breast cancer cells. Oncogene. 19:2000;4066-4070.
72. Bovenzi V., Momparler R.L. Antineoplastic action of 5-aza-2′-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells. Cancer Chemother. Pharmacol. 48:2001;71-76.
73. Sirchia S.M., Ferguson A.T., Sironi E., Subramanyan S., Orlandi R., Sukumar S., Sacchi N. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells. Oncogene. 19:2000;1556-1563.
74. Bunone G., Briand P.A., Miksicek R.J., Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 15:1996;2174-2183.
75. Campbell R.A., Bhat-Nakshatri P., Patel N.M., Constantinidou D., Ali S., Nakshatri H. PI3 kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J. Biol. Chem. 276:2001;9817-9824.
76. Lee H.-J., Suh Y.-A., Robinson M.J., Clifford J.L., Hong W.K., Woodgett J.R., Cobbs M.H., Mangelsdorf D.J., Kurie J.M. Stress pathway activation induces phosphorylation of retinoid X receptor. J. Biol. Chem. 275:2000;32193-32199.
77. Tahayato A., Lefebvre P., Formstecher P., Dautrevaux M. A protein kinase C-dependent activity modulates retinoic acid-induced transcription. Mol. Endocrinol. 7:1993;1642-1653.
78. Lee C.S., deFazio A., Ormandy C.J., Sutherland R.L. Inverse regulation of oestrogen receptor and epidermal growth factor receptor gene expression in MCF-7 breast cancer cells treated with phorbol ester. J. Steroid Biochem. Mol. Biol. 58:1996;267-275.
79. Oh A.S., Lorant L.A., Holloway J.N., Miller D.L., Kern F.G., El-Ashry D. Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol. Endocrinol. 15:2001;1344-1359.
80. Delmotte M.-H., Tahayato A., Formstecher P., Lefebvre P. Serine 157, a retinoic acid receptor α residue phosphorylated by protein kinase C in vitro, is involved in RXR-RARα heterodimerisation and transcriptional activity. J. Biol. Chem. 274:1999;38225-38231.
81. Rochette-Egly C., Adam S., Rossignol M., Egly J.M., Chambon P. Stimulation of RAR alpha activation function AF-1 through binding to the general transcription factor TFIIH and phosphorylation by CDK7. Cell. 90:1997;97-107.
82. Feng W., Webb P., Nguyen P., Liu X., Li J., Karin M., Kushner P.J. Potentiation of estrogen receptor activation function 1 (AF-1) by Src/JNK through a serine 118-independent pathway. Mol. Endocrinol. 15:2001;32-45.
83. Rogatsky I., Trowbridge J.M., Garabedian M.J. Potentiation of human estrogen receptor alpha transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex. J. Biol. Chem. 274:1999;22296-22302.
84. Rowan B.G., Weigel N.L., O'Malley B.W. Phosphorylation of steroid receptor coactivator-1. J. Biol. Chem. 275:2000;4475-4483.
85. Veronesi U., De P.G., Costa A., Formelli F., Decensi A. Chemoprevention of breast cancer with fenretinide. IARC Sci. Publ. 136:1996;87-94.